Aishi achieved positive top-line results in phase 3 trials on the treatment of sleep-wake disorders in the study drug lemborexant

recently, Eisai and Purdue Pharma announced that their sleep-wake cycle swashesdrug(in the phase 3trial(2) for the treatment of sleep-wake disordersabout the small molecular compound lemborexant found and developed, is an antagonist in the study of the dual appetite hormone (orexin) receptor, which suppresses the signaling of appetite hormone by combining with competition with appetite receptor subtypes 1 and 2During normal sleep, the activity of the appetite-insin system that regulates the sleep and wake cycle strains is suppressedIn patients with sleep-wake disorder, given that their appetite-inscentatoin system, which regulates awakening, may not function properly, the signaling through purposeful antagonists can be achieved to counteract abnormal awakenings and promote sleep and sleep maintenanceas a result, Vesa and Purdue have been developing lemborexant as a drug for insomnia and a variety of sleep disordersstudiesA 12-month phase 3 trial of SUNRISE 2 is still in progress, and in 971 insomnia patients between the ages of 18 and 88, the aim was to assess the effectiveness and safety of adjusting sleep-wakes in two different doses of lemborexant, 5 mg and 10 mgAt 6 months, both doses of lemborext reached the primary and critical secondary therapeutic ends compared to placebopatients treated with lemborexant had a statistically significant improvement in their sleeptime, while subjective sleep efficiency and subjective awakening spree were improved after falling asleepIn addition, two doses of lemborexant improved the "daily life function" of patients assessed by the Insomnia Severity IndexAoki and Purdue plan tothe 2019 Medical Conference (above to announce the full results of the SUNRISE 2 trial)